We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants

5 hedge funds and large institutions have $8.8K invested in Pasithea Therapeutics Warrants in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less capital invested

Capital invested by funds: $9.59K → $8.8K (-$789)

17% less funds holding

Funds holding: 65 (-1)

33.86% less ownership

Funds ownership: 49.55%15.69% (-34%)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
KC
1
Kepos Capital
New York
$7K
AC
2
Armistice Capital
New York
$1.08K
MG
3
Marex Group
$388
Citadel Advisors
4
Citadel Advisors
Florida
$335 +$307 +15,511 New
CS
5
Clear Street
New York
$2
WAM
6
Warberg Asset Management
Illinois
-$2.03K -100,000 Closed
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
-$193 -10,579 Closed

KTTAW Hedge Fund Activity: Q2 2025 in Review

5 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q2 2025, worth a combined $8.8K — down 8.2% from $9.59K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of KTTAW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $307. The largest seller was Warberg Asset Management, exiting entirely with an estimated $2.03K sold.

  • 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q2 2025, down from 6 in Q1 2025.
  • Funds reported $8.8K of Pasithea Therapeutics Warrants stock for Q2 2025, down 8.2% quarter-over-quarter.
  • 1 fund opened new Pasithea Therapeutics Warrants positions in Q2 2025 and 2 closed out, a net change of -1 holder.
  • The largest Pasithea Therapeutics Warrants buyer in Q2 2025 was Citadel Advisors, an estimated $307 added.
  • The largest Pasithea Therapeutics Warrants seller in Q2 2025 was Warberg Asset Management, an estimated $2.03K sold.

Based on aggregated 13F filings for Q2 2025.